Salix Pharmaceuticals' (SLXP) shares rose 9% on a positive earnings report.
The gastrointestinal drug developer earned $6.9 million, or 14 cents a share, during the second quarter. Excluding certain charges, earnings were $7.8 million, or 16 cents a share. Analysts were expecting earnings of 15 cents a share.
Revenue rose 51% from a year ago to $52.9 million, thanks partly to Xifaxan prescription growth of 122% over the prior year. Xifaxan is indicated for the treatment of travelers' diarrhea associated with the bacteria Escherichia coli. Analysts were expecting revenue of $51 million. Shares gained 95 cents to $11.34.
Kos Pharmaceuticals (KOSP) shares rose 5% on an earnings beat.
Kos earned $13.9 million, or 28 cents a share, down from $28.9 million, or 61 cents a share. However, excluding certain one-time charges, the company earned 59 cents a share. Analysts surveyed by Thomson First Call were expecting earnings of 42 cents a share.
Revenue also exceeded expectations, reaching $223.7 million, compared with estimates of $215.3 million.
Barrier Therapeutics (BTRX) shares fell 13% after losses widened.
The drug developer lost $13.9 million, or 58 cents a share, for the second quarter, compared with a year-ago loss of $10.8 million, or 45 cents a share. Analysts were expecting a loss of 53 cents a share.
Revenue more than doubled to $1.08 million from $472,000 a year ago. Shares fell 86 cents to $5.55.
Investors in Inspire Pharmaceuticals (ISPH) fell 8% on a second-quarter loss.
Inspire's net loss widened to $5.4 million, or 13 cents a share, from the year-ago $4.7 million, or 11 cents a share. Analysts were expecting a loss of 18 cents a share. Revenue in the second quarter was $13.4 million, compared with $9.6 million a year ago.
Among other health stocks sinking Tuesday were Celgene (CELG) , down 2.5% to $44; Medtronic (MDT) , off 1.2% to $43.26; Northfield Laboratories (NFLD) , down 2.3% to $11.35; and Momenta Pharmaceuticals (MNTA) , down 9.8% to $14.80.
Among health stocks rising were Genetic Technologies (GENE) , up 9.6% to $8.25; AMN Healthcare Services (AHS) , up 6.8% to $22.54; InterMune (ITMN) , up 3.8% to $15.98; and Valeant Pharmaceuticals (VRX) , up 2.8% to $18.59.
The gastrointestinal drug developer earned $6.9 million, or 14 cents a share, during the second quarter. Excluding certain charges, earnings were $7.8 million, or 16 cents a share. Analysts were expecting earnings of 15 cents a share.
Revenue rose 51% from a year ago to $52.9 million, thanks partly to Xifaxan prescription growth of 122% over the prior year. Xifaxan is indicated for the treatment of travelers' diarrhea associated with the bacteria Escherichia coli. Analysts were expecting revenue of $51 million. Shares gained 95 cents to $11.34.
Kos Pharmaceuticals (KOSP) shares rose 5% on an earnings beat.
Kos earned $13.9 million, or 28 cents a share, down from $28.9 million, or 61 cents a share. However, excluding certain one-time charges, the company earned 59 cents a share. Analysts surveyed by Thomson First Call were expecting earnings of 42 cents a share.
Revenue also exceeded expectations, reaching $223.7 million, compared with estimates of $215.3 million.
Barrier Therapeutics (BTRX) shares fell 13% after losses widened.
The drug developer lost $13.9 million, or 58 cents a share, for the second quarter, compared with a year-ago loss of $10.8 million, or 45 cents a share. Analysts were expecting a loss of 53 cents a share.
Revenue more than doubled to $1.08 million from $472,000 a year ago. Shares fell 86 cents to $5.55.
Investors in Inspire Pharmaceuticals (ISPH) fell 8% on a second-quarter loss.
Inspire's net loss widened to $5.4 million, or 13 cents a share, from the year-ago $4.7 million, or 11 cents a share. Analysts were expecting a loss of 18 cents a share. Revenue in the second quarter was $13.4 million, compared with $9.6 million a year ago.
Among other health stocks sinking Tuesday were Celgene (CELG) , down 2.5% to $44; Medtronic (MDT) , off 1.2% to $43.26; Northfield Laboratories (NFLD) , down 2.3% to $11.35; and Momenta Pharmaceuticals (MNTA) , down 9.8% to $14.80.
Among health stocks rising were Genetic Technologies (GENE) , up 9.6% to $8.25; AMN Healthcare Services (AHS) , up 6.8% to $22.54; InterMune (ITMN) , up 3.8% to $15.98; and Valeant Pharmaceuticals (VRX) , up 2.8% to $18.59.
posted by doublezero at
3:00 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home